Home > Products > Novel inhibitors
Cat. No. Product name CAS No.
DCC1676 Daw-22

Biological Active Reagents

DCC1677 Db07107

Novel tyrosine kinase inhibitor for drug resistant T315I mutant BCR-ABL

552332-71-5
DCC1678 Db1255

Novel ERG/DNA binding inhibitor, targeting the DNA-binding activity of the human ERG transcription factor

DCC1679 Db1960

Novel antileishmanial agent, against both intracellular Leishmania donovani and intracellular Leishmania amazonensis and displaying dose-dependent reduction of liver parasitemia

DCC1680 Dbco-stco

Novel protein cross-linking agent

DCC1681 Dbm-1285 Dihydrochloride

p38 MAPK inhibitor, supressing p38 phosphorylation and LPS-induced TNF-α production in macrophages

917811-28-0
DCC1682 Dbpr110

Potent HCV NS5A inhibitor

1310694-75-7
DCC1683 Dc_501

Novel selective non-nucleoside inhibitor of DNA methyltransferase 1 (DNMT1)

889797-65-3
DCC1684 Dc_m5_2

Novel inhibitor of WDR5-MLL1 interaction

713099-37-7
DCC1685 Dc_ym21 Maleate

Novel inhibitor of menin-MLL interaction

2001072-35-9
DCC1686 Dc_ym25

Novel inhibitor of menin-MLL interaction

DCC1687 Dc_ym26

Novel inhibitor of menin-MLL interaction

DCC1688 Dcat Maleate [57915-90-9]

Inhibitor of N-methyl transferases (NMT), preventing the formation of Parkinson's syndrome neurotoxins via methylation of non-methylated pre-neurotoxins.

57915-90-9
DCC1689 Dc-bpi-11

Novel potent BPTF-BRD inhibitor, showing selectivities 100-fold higher than those of other BRD targets, significantly inhibiting leukemia cell proliferation

DCC1690 Dc-bpi-7

Novel potent BPTF-BRD inhibitor, showing selectivities 100-fold higher than those of other BRD targets

DCC1691 Dc-cpin734

Novel potent CBP bromodomain inhibitor with a TR-FRET IC50 value of 19.5 ± 1.1 nM and over 400-fold of selectivity against BRD4 bromodomains

DCC1692 Dce_254

Novel potent EZH2 inhibitor

673443-80-6
DCC1693 Dce_42

Novel potent EZH2 inhibitor

669749-45-5
DCC1694 Dc-ebio

Activator of IK and SK channels

60563-36-2
DCC1695 Dcg066

Novel inhibitor of lysine methyltransferase G9a

494786-13-9
DCC1696 dcg-iv

Highly potent agonist for group II mGlu receptors

147782-19-2
DCC1697 Dc-k2in212

Novel potent CDK2 inhibitor with selectivities above 10-fold over CDK1/4/6/7/9/12 above 10-fold, displaying anti-proliferative activity against A2058 melanoma and MV4-11 leukemia cell lines and low toxicity on human normal cell lines, inhibiting CDK2-medi

Page 1298 / Total 1557 FirstPrevNextLastGoto